Allergan Plc (AGN)

154.64
3.80 2.50
NYSE : Health Technology
Prev Close 150.84
Open 150.84
Day Low/High 150.84 / 154.77
52 Wk Low/High 125.84 / 197.00
Volume 1.53M
Avg Volume 3.13M
Exchange NYSE
Shares Outstanding 332.61M
Market Cap 50.31B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.94%)
Allergan Says It's Looking to Sell Two of Its Units, But Not at Fire-Sale Prices

Allergan Says It's Looking to Sell Two of Its Units, But Not at Fire-Sale Prices

The Dublin-based drugmaker has wrapped up a strategic review of all its businesses, but says it's not pursuing a fire sale of its assets.

Weekly Roundup

China trade wars, North Korea tensions and oil volatility hit the markets this week.

Aegon Calls EUR 200 Million Of Perpetual Capital Securities

Aegon Calls EUR 200 Million Of Perpetual Capital Securities

Aegon announces that it is exercising its right to redeem the EUR 200 million 6% perpetual capital securities.

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer weighs in on Royal Caribbean, Allergan, Tyson Foods, Carrizo Oil & Gas, Valeant Pharmaceuticals, Okta, CRISPR Therapeutics and more.

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Jim Cramer says the hope that the trade dispute with China can be worked out was the fuel for this rally.

Weekly Roundup

Markets consolidate after recent gains

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

Annual Meeting Of Shareholders Adopts All Resolutions

Annual Meeting Of Shareholders Adopts All Resolutions

Aegon N.V.

Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

Here's what you need to know now for Thursday, May 17.

Allergan's Meury Talks Market Expansion in Aesthetics

Allergan's Meury Talks Market Expansion in Aesthetics

The chief commercial officer's appearance at a Bank of America healthcare conference came a day after Allergan competitor Evolus said it had received a complete response letter regarding its application for Botox rival DWP-450.

Jim's Daily Rundown

Jim discusses Macy's quarter as a readthrough to Nordstrom, defense and North Korea, and more on the market!

Jana Partners Takes Positions in Adobe, Apple, Anthem, AutoDesk, Others

Jana Partners Takes Positions in Adobe, Apple, Anthem, AutoDesk, Others

The insurgent manager who helped engineer the Amazon-Whole Foods combination opened a window into his latest allocations, any of which could become campaigns. Here's a wrap up of his investments as well as new developments from Mick McGuire's Marcato Capital and Dan Loeb's Third Point.

Weekly Roundup

The markets strongly rebounded this week as a few of the major averages pushed into positive year-to-date territory.

Allergan Becomes #231 Most Shorted S&P 500 Component, Replacing Ross Stores

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Allergan Expects to Finish Strategic Review Quickly, CFO Says

Allergan Expects to Finish Strategic Review Quickly, CFO Says

The Dublin-based drugmaker will provide communications on the strategic review in 'weeks, not months,' Allergan CFO Matthew Walsh said at the Deutsche Bank healthcare conference.

Weekly Roundup

A strong Friday failed to keep markets in positive territory.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Aurobindo Pharma Ltd.

Jim Cramer: Markets Expect Too Much from Under Armour, IBM and These Other Names

Jim Cramer: Markets Expect Too Much from Under Armour, IBM and These Other Names

The stocks inexplicably fell even after they delivered good earnings.

Jim's Daily Rundown

Jim discusses the trade tariff deadline extension, Emerson Electric's earnings, last night's interview with Allergan CEO Brent Saunders, Goldman Sachs, 3M and more!

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Jim Cramer makes the calls on Alibaba, First American, Coherent, Ionis Pharmacuetical, Skechers USA, Corning, Bank of Internet and more.

Ventas: Cramer's Top Takeaways

Ventas: Cramer's Top Takeaways

Debra Cafaro, chairman and CEO of Ventas, tells Jim Cramer about the company's investment in university research facilities.

Allergan: Cramer's Top Takeaways

Allergan: Cramer's Top Takeaways

Brent Saunders, chairman and CEO of Allergan, talks to Jim Cramer about the company's drug pipeline, and Botox.

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Love the banks, then hate the banks. Love the industrials? Nope, they're out, too. Jim Cramer says it's ugly, but he would use the weakness in the upside surprises.

Dow, S&P 500 and Nasdaq Decline as M&A Fails to Push Wall Street Higher

Dow, S&P 500 and Nasdaq Decline as M&A Fails to Push Wall Street Higher

Stocks finished lower as Wall Street processes a mega-merger between Sprint and T-Mobile US and as Walmart says it will sell its supermarket business in the U.K.

Allergan Is Still In a Downtrend as We Wait for a Bottom to Form

Allergan Is Still In a Downtrend as We Wait for a Bottom to Form

Allergan's bottom is going to take more time.

Allergan First Quarter Earnings

The market is looking past the positive results as the commentary surrounding the breakup overshadowed the earnings.

Jim's Daily Rundown

Jim discusses Allergan, Apple, broken stocks vs. broken companies and more!

Video: Jim Cramer on T-Mobile, Sprint, AT&T, Centene and Allergan

Video: Jim Cramer on T-Mobile, Sprint, AT&T, Centene and Allergan

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending stocks from the floor of the New York Stock Exchange.

Selling Some Lilly; Adding to PepsiCo

We will make a small sale in LLY and use the proceeds and opportunity to scoop up more PEP.

TheStreet Quant Rating: D+ (Sell)